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With biomimetic biomaterials, like calcium phosphate cements (CPCs), non-invasive assessment of tissue
regeneration is challenging. This study describes a theranostic agent (TA) to simultaneously enhance
both imaging and osteogenic properties of such a bone substitute material. For this purpose, mesoporous
silica beads were produced containing an iron oxide core to enhance bone magnetic resonance (MR)
contrast. The same beads were functionalized with silane linkers to immobilize the osteoinductive
protein BMP-2, and finally received a calcium phosphate coating, before being embedded in the CPC.
Both in vitro and in vivo tests were performed. In vitro testing showed that the TA beads did not interfere
with essential material properties like cement setting. Furthermore, bioactive BMP-2 could be efficiently
released from the carrier-beads. In vivo testing in a femoral condyle defect rat model showed long-term
MR contrast enhancement, as well as improved osteogenic capacity. Moreover, the TA was released
during CPC degradation and was not incorporated into the newly formed bone. In conclusion, the
described TA was shown to be suitable for longitudinal material degradation and bone healing studies.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The growing need for bone treatment procedures keeps a high
pressure on the development and optimization of artificial sub-
stitutes for bone regeneration. Calcium phosphate (CaP) based
materials are amongst the most commonly used, as they closely
resemble structure and composition of the natural bone. Especially,
injectable CaP-based cements (CPCs) have the advantage of optimal
bone defect filling capacity, and are applicable through minimally
invasive surgery [1]. The osteoinductivity of such materials can be
enhanced by incorporating biologically active molecules, like BMP-
2, either via adsorption onto pre-set CPC scaffolds [2], or via loading
before the CPC setting.
At the same time, assessment of tissue regeneration is essential
to optimize the stages of bone healing. Most commonly, bone.nl, j.jansen@dent.umcn.nl
All rights reserved.healing is assessed with X-ray or computed tomography (CT) as-
sessments. Recently, also zero echo time (ZTE) magnetic resonance
imaging (MRI) [3], has proved to be a powerful tool for bone tissue
imaging. However, all commonly used techniques for bone imaging
lack sensitivity to detect the presence of synthetic bone substitutes,
without additional contrast enhancement. Advances in the fields of
material science, imaging and formulation development lead to the
development of theranostics, which aims at combining both ther-
apeutic (e.g. the BMP-2) and diagnostic (e.g. the MR detection)
functionswithin a single product. Theranostic medicine is currently
explored to enhance the quality of cancer treatments, atheroscle-
rosis, infections, and a variety of regenerativemedicine applications
[4]. In this study, we have developed a theranostic agent (TA), a
silica-based nanocomposite MR contrast agent, which also func-
tions as carrier for BMP-2 release. The specific formulation of such a
composite, combinedwith the biocompatibility of silica, is meant to
provide imaging contrast enhancement, while reducing unspecific
reactivity and improving the osteogenic performance of CPCs. After
Table 1
Experimental groups and implantation scheme. With the aim of testing both the MR
contrast agent and BMP-2 performance, four experimental groups were selected: (i)
Empty e untreated defect, (ii) CPC e defect filled with injectable calcium CPC, (iii)
MRI e defect filled with injectable CPC incorporating the MR contrast agent and (iv)
MRI/BMP2 e defect filled with injectable CPC incorporating the MR contrast agent
and BMP-2.











M. Ventura et al. / Biomaterials 35 (2014) 2227e22332228in vitro characterization, the developed TA was tested in vivo, in a
femoral condyle defect model in rats. Imaging properties were
monitored byMRI, while osteogenic performancewas measured by
histomorphometry, up to 8 weeks post-implantation.
2. Materials and methods
2.1. CaP cement with PLGA microspheres
Calcium phosphate cement consisted of 85% of a-tricalcium phosphate, 10%
dicalcium phosphate dihydrate and 5% hydroxyapatite [5]. The cement powder was
sterilized using gamma radiation with 25 kGy (Isotron B.V., Ede, The Netherlands).
As a porogen, acid-terminated PLGA microparticles were prepared using a double-
emulsion solvent-extraction technique. Poly (DL-lactic-co-glycolic acid), (PUR-
ASORB, Purac, Gorinchem, The Netherlands) with a lactic to glycolic acid ratio of
50:50 and an average molecular weight of 4.55  0.03 kDa, was used for micro-
particle preparation. The average size of the microparticles, as determined with
image analysis, was 96  16 mm [6]. PLGA microparticles were mixed with the CaP
cement powder in a proportion of 20% wt/wt.
2.2. Theranostic agent
A customized theranostic agent (TA) was synthesized. The contrast agent par-
ticles were prepared by an inverse emulsion approach (patent WO2005/052581;
Nano4Imaging GmbH, Aachen, Germany) using MRI responsive ultra small iron
particles (USPIO) embedded within a mesoporous silica matrix. Two contrast agent
formulations were tested: (i) MRI-1 with an iron oxide core size range of 200e
300 nm at an end concentration of 40% wt/wt, and (ii) MRI-2 with an iron oxide core
size range between 0.5 and 1.2 mm at an end concentration of 30% wt/wt.
BMP-2 (Pfizer, InductOs former Wyeth Europe Ltd., Berkshire, UK) was
immobilized onto the surface of the beads, functionalized with silane linkers car-
rying amino functions (3-aminopropyl-trimethoxysilane), as described by Elhert
et al. [7]. A solution containing 10 mg of BMP-2wasmixedwith a suspension of beads
(12.5 mL at a concentration of 20 mg/mL) in phosphate-buffered saline (PBS) buffer
(pH 6.8). PBS was then removed and the beads were resuspended in 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (pH 5.5) and placed at 4 C, overnight.
Finally, the TA beads were given a calcium phosphate coating. For this, 500 mL of
a 5 mg/mL contrast agent suspension, containing 10 mg of BMP-2, was mixed with
54 mL of 40 mM CaCl2, 77 mL of 3.9 mM Na2HPO4 and 60 mL of 1 mM NH3. The mixture
was placed at 4 C for 1 h. After pH had reached 7.9, 60 mL of 1 mM NH3 was added
into the solution, and again placed at 4 C for 1 h.When pHwas 8.5, again 80 mL 1mM
NH3 was added and the solution remained at 4 C for 1.5 h. The final pH was 9.5. The
suspension was maintained under continuous rotation throughout the entire pro-
cedure. The resulting coated beads were magnetically separated and washed 4 times
in PBS. The precipitate was then diluted to an end concentration of 20 mg/mL.
Control samples were treated the same way, with exception that the beads did not
contain BMP-2. After freeze-drying, the obtained solid phase was then mixed to
reach a final end concentration of 0.1% (wt/wt) within the bone cement/PLGA
composite.
2.3. Composite preparation
The cement was created by adding a filtered sterilized (0.2 mm filter) 2% aqueous
solution of sodium phosphate (Na2HPO4) to the PLGA/CaP or PLGA/CaP/TA powder
mixture using a 2-mL syringe (BD Plastipak, Becton Dickinson S.A., Madrid, Spain)
with a closed tip. The components were shaken for 20 s using a mixing apparatus
(Silamat Vivadent, Schaan, Liechtenstein).
2.4. Characterization of CPC and TA
2.4.1. Theranostic agent-beads
The morphology of the TA beads was determined by SEM and transmission
electron microscopy (TEM). SEM images were obtained at 2000, 5000 and
10,000 magnification, while TEM images were obtained at 30K and 50K.
Elemental analysis was performed using a scanning electron microscope (SEM,
Philips XL30, Eindhoven, The Netherlands) coupled with an energy dispersive X-ray
spectrometer (EDS, EDAX, AMETEK Materials Analysis Division, Mahwah, NJ).
Samples were sputtered with a thin layer of gold using a common sputtering in-
strument (Cressington 108A, Watford, UK) to improve the surface conductivity. The
EDS elemental maps were taken at accelerating voltage of 15 KeV and working
distance of 10 mm.
2.4.2. CPC
Initial and final setting times for the different cement formulations were
assessed using custom available Gillmore needles (ASTM C266). A plastic mould of
3 mm (diameter) 6mm (height) was used to prepare the scaffolds. Both initial and
final setting times were determined and tests were performed at room temperature.
Thereafter, for mechanical testing samples were placed on an 858 MiniBionixII
testing bench (MTS, Eden Prairie, MN) and the compressive strength in the longi-
tudinal direction of the specimens was measured at 0.5 mm/min cross-head speed.
Finally, to assess morphology all different cement formulations were assessed byscanning electron microscopy (SEM). For this purpose, destructed samples were
obtained from the compression test. Images were obtained at 500, 1000 and
2000 magnification.
2.5. Ex vivo MRI
Sixteen explanted rat femoral condyles were collected, which were left-over
material from unrelated experiments (RU-DEC 2012-317). In each condyle, a cylin-
drical defect was made of 3.0 mm depth and diameter; and filled bearing either the
contrast agentMRI-1 or MRI-2 mixed into the CPC, at a concentration of both 0.1 and
0.5% wt/wt (n ¼ 4 for each condition). After 30 min, condyles were immersed in 70%
ethanol and MR imaging was performed on a 11.7T MR system (Biospec, Bruker,
Germany) with a mouse brain surface coil. Zero echo time (ZTE) images were ac-
quired for all samples at the same time and settings, to avoid confounding effects of
individual calibration or thresholding, at 200 kHz bandwidth, TR ¼ 4 ms, flip
angle ¼ 5 , FOV ¼ 50  50  50 mm, matrix size 128  128  128, total acquisition
time 3.27 min.
2.6. BMP-2 immobilization and release
Following BMP-2 immobilization, the amount of BMP-2 effectively bound to the
surface of the beads was measured. Thereafter, BMP-2 release tests were performed
and the protein concentration was measured by both ELISA, to quantify all released
BMP-2, and BRE-Luc assay, to specifically quantify the fraction of bioactive BMP-2.
2.6.1. Quantification of effectively bound BMP-2
The fraction of BMP-2 bound to the silica beads was determined by enzyme-
linked immunosorbent assay ELISA assays, with a Quantikine BMP-2 immuno-
assay kit (R&D Systems, Minneapolis, MN) following the manufacturer’s in-
structions. The assay was performed for all process steps, i.e. (i) on the MES buffer
used for the immobilization, and removed during the first washing step, (ii) on the
PBS collected after the following washing steps, and finally (iii) on the resulting
beads.
2.6.2. Quantification of released BMP-2
A 12.5 mL aliquot of the bead suspensions, loaded with BMP-2 was resuspended
in 500 mL of minimum essential medium alpha (MEM-a). Both coated and non-
coated samples remained in the medium for 2 h, 3 days and 7 days. The amount
of BMP-2 released into the supernatants was determined using ELISA (R&D Systems)
and BRE-Luc assay, described below.
2.6.3. BRE-Luc assay
M3T3-BRE-Luc cells were cultured in Dulbecco’s modified eagle’s medium
(DMEM) containing 5% fetal bovine serum (FBS) and 800 mg/mL neomycine, at 37 C
in a humidified atmosphere of 5% CO2. Cells were trypsinized and seeded at a
concentration of 2  104 in 100 mL of 5% FCS-DMEM in a flatbottomed transparent
plate for 24 h. After removing the culture medium, 100 mL of the samples medium,
containing the released BMP-2, were added into the wells, together with 2% FBS. To
estimate BMP-2 release, a standard curve obtained with soluble BMP-2 in dilutions
from 0.4 until 50 ng/mL (100 mL/well) was performed in parallel. Following the in-
cubation time of 16e20 h, the medium was removed and replaced by 25 mL of re-
porter lysis buffer (Promega, Madison, WI). The incubationwas done at80 C for at
least 1 h. After defrosting, 25 mL of Bright glow (Promega) were added to each well
and the luciferase intensity was measured (LUMIstar Omega, BMG LABTECH GmbH,
Ortenberg, Germany).
Fig. 1. Morphological characterization of the TA beads. a. SEM micrograph of the TA particles at 1000 magnification; b. TEM image of a single TA particle before CaP coating, at a
magnification of 50K. The more electron dense inner iron core appears darker, while the surrounding silica matrix appears lighter. c. Elemental analysis of the final TA performed
using SEM coupled with an EDS. Spatial distribution maps and relative abundance of the single elements are herein presented as atomic percentage. The upper right image shows
the overlap of all detected elements.
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2.7.1. Animal model
All in vivo work was conducted in accordance with standards and protocols of
the Radboud University Medical Center, Nijmegen, The Netherlands. National
guidelines for care and use of laboratory animals were obeyed and approval of the
Experimental Animal Ethical Committee was obtained (RU-DEC 2012-060). Ten
healthy adult male Wistar rats, weighing 250e300 g were included as experimental
animals. Surgery was performed under general inhalation anesthesia (Isoflurane)
and aseptic conditions. For the surgical procedure animals were immobilized and
both legs were shaved, washed and disinfected. The knee joint was exposed after a
longitudinal parapatellar incision. At the femoral intercondylar notch, a cylindrical
defect (3.0 mm depth and diameter) was then prepared using a dental bur and
continuous external cooling with saline. Defects were filled with the various CPC
materials, or left untreated in control animals (Table 1), before the subcutaneous
tissue and skinwere closed by suturing in layers. In vivoMR scans were performed 4
and 8 weeks post-surgery. Thereafter, animals were sacrificed and histology and
micro-CT were performed.
2.7.2. In vivo MRI
MR imagingwas performed 4 and 8weeks after surgery using a 11.7TMR system
(Biospec, Bruker, Germany) with a home-built bare Helmholtz coil with a size of
3  3 cm. Zero echo time imaging was performed at 200 kHz bandwidth, TE/
TR ¼ 0 ms/8 ms, flip angle ¼ 5 , FOV ¼ 50  50  50 mm, matrix size:
128  128  128, 4 averages and a final acquisition time of 30.27 min.
2.8. Micro-CT
Eight weeks after surgery, the animals were sacrificed by CO2/O2 overdose.
Femoral condyles were retrieved and surrounding soft tissue was removed. Bone
samples were fixed in 10% formalin for 48 h and subsequently transferred to 70%
ethanol for the duration of the mCT scans. For 3D analysis, the specimens were placed
vertically onto the sample holder of a micro-CT imaging system (Skyscan 1072,
Kontich, Belgium). Subsequently, samples were recorded at a 11.10 mm resolution (X-
ray source 100 kV/98 mA; Exposure time 3.9 s; 1 mm filter applied). Then, using
NRecon V1.4 (SkyScan), a cone beam reconstructionwas performed on the projected
files. Finally, 3D-reconstructions of the samples were obtained (3D-DOCTOR 4.0,
Able Software Corp, Lexington, MA).2.9. Histology
After scanning, all specimens were decalcified for 72 h in 10% ETDA. Samples
were then dehydrated in gradual series of ethanol (70%e100%) and embedded in
Paraffin. Sections of 6 mm thickness were cut in a plane parallel to the long axis of the
femur using a Leica RM2165 Microtome (Leica Microsystems, Rijswijk, The
Netherlands). The sections were stained with haematoxylin/eosin and trichrome
Elastin van Gieson (EVG); at least six sections of each specimen were analyzed.
2.10. Bone quantification
The EVG-stained slides were quantitatively assessed using computer-based
image analysis techniques (Leica Qwin Pro-image, Leica, Wetzlar, Germany). From
digitalized images (magnification 2.5), the percentage of bone tissue was deter-
mined within the area of interest, positioned accordingly to the original size and
position of the created defect.
2.11. Statistical analysis
Statistical analysis for bone quantification was performed using GraphPad
Instat (GraphPad Software, San Diego, CA). Statistical comparisons were performed
by one-way analysis of variance with a Tukey multiple comparison post-test. For
setting time and compression tests, data are presented as mean  standard devia-
tion and significant differences were determined by analysis of variance (ANOVA).
All differences were considered significant at P-values <0.05.
3. Results
3.1. Characterization of TA beads
As evident from the SEM micrographies, the beads presented a
uniform size distribution (Fig. 1a), with a mean value of 1.68  0.86
for MRI-1 and 1.65 0.78 mm for MRI-2. From the TEM image it was
possible to identify the inner iron core which appears darker, as
more electron dense, surrounded by the silica matrix (Fig. 1b). As
shown in Fig. 1c, five principal elements could be detected: silicon
M. Ventura et al. / Biomaterials 35 (2014) 2227e22332230(Si) and oxygen (O) as components of the silica matrix, phosphorus
(P) and calcium (Ca) from the most superficial coating layer, and
iron (Fe) from the inner core. The spatial distribution of Fe, O and Si
was homogeneous throughout the entire field of view, delimited by
the SEM micrography. Differently, despite being well-distributed
throughout the whole sample, presence of Ca and P showed
evident variability even within the single beads.
3.2. Characterization of CPC/TA
All formulations showed a uniformly distributed appearance of
the TAwithin the cement powder (Fig. 2a). At both the 0.1 and 0.5%Fig. 2. Characterization of CPC/TA composite. a. SEM micrograph of TA particles
(indicated by red arrows) mixed within the CPC matrix at 1000 magnification. Note
that the TA is uniformly distributed within the cement matrix. b. Ex vivo MR
imaging performance of smaller diameter/higher concentration MRI-1 vs. larger
diameter/lower concentration MRI-2 agents, at two different concentrations. Note that
0.1% w/w MRI-2 was the optimal combination providing MR-contrast enhancement.
(For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)wt/wt concentrations, no differences were measured in initial or
final setting time with the incorporation of MRI-1. The addition of
MRI-2 caused a significant increase of the final setting time from
approximately 18e20 min. When assessing the material compres-
sion strength, only the highest concentration of MRI-2 caused a
significant decrease (Table 2).
3.3. Ex vivo MRI
Obvious CPC-to-bone contrast enhancement was seen in all
samples. For the MRI-1 formulationwith a lower core diameter, yet
higher iron concentration, contrast wasmostly characterized by the
presence of a so-called blooming artifact. Further, at the settings
used both applied concentrations led to a considerable visual
overestimation of the size, with regards to the original defect
perimeter. In contrast, the higher core diameter, lower iron con-
centration MRI-2 formulation proved to be optimal, as by visual
inspection the contrast enhancement was corroborating closely
with the original defect morphology (Fig. 2b). Based on this evi-
dence, MRI-2 at a concentration of 0.1% wt/wt was selected only for
the following tests and the final in vivo evaluation.
3.4. BMP-2 immobilization and release
The amount of BMP-2 immobilized on the surface of the beads
was measured by ELISA. The assay showed that it was possible to
immobilize relatively high amounts of BMP-2 on the substrates
using an aminosilane linker. The measured amount was about
4.97  0.86 mg of BMP-2 per 12.5 mL bead suspension, i.e. approx-
imately 50% of the originally added 10 mg.
The remaining 1.98 0.72 mg weremeasured in the supernatant
and 2.54  1.81 in the washing medium.
To quantify the released BMP-2 and its biological activity, the
complementary ELISA and BRE-Luc tests were carried out. Both
detection methods showed a progressive release during the
observational period of 7 days. The presence of the hydroxyapatite
coating induced a double amount of growth factor to be released
after both 3 and 7 days, compared to the non-coated beads (Fig. 3a).
BRE-Luc data (Fig. 3b) showed that at least half of the released
protein measured by ELISA remained biologically active.
3.5. In vivo MRI
The surgical procedure did not lead to any adverse and unex-
pected reactions. All animals recovered within a few hours post-
surgery and none were restricted in their movements. Rats were
monitored during the whole experimental period and no evident
signs of discomfort nor weight loss were observed. Eight weeks
post-implantation, all femoral condyles were retrieved. At a mac-
roscopical visual inspection, no clear differences were observed
between the Empty, CPC and MRI groups, whereas obvious areas of
new bone formation were detected in the group containing BMP-2.
MR images obtained 4 weeks post-implantation showed a par-
tial healing of the untreated bone defects, which appeared to be
progressed at week 8. No reliable observations could be made
within the CPC group without additives, as the implanted material
could not be reliably localized among the surrounding natural bone
at either time point. In contrast, the incorporation of the MRI-2
contrast agent provided information about the correct localiza-
tion of the injectedmaterial. Interestingly, also one undesired event
could immediately be found, i.e. the formation of an evident crack
in the center of one of the implanted cements. In this group, the
MRI-2 contrast enhancement could still be detected 8 weeks
following the implantation. Finally, similar contrast was observed
at 4 weeks in the presence of the MRI-2/BMP-2 sample. This
Table 2
Comparison of size of the TA beads and effect on setting time. Two sets of beads incorporating different contrast agents formulations, namely MRI-1 andMRI-2, at both 0.1 and










CPC e e 3.91  0.22 17.94  0.44 75.99  20.51
MRI-1 0.1% w/w 0.2e0.3 1.68  0.86 3.94  0.36 18.64  0.43 68.06  9.16
MRI-1 0.5% w/w 0.2e0.3 1.68  0.86 4.98  0.44 19.52  0.43 66.80  9.87
MRI-2 0.1% w/w 0.5e1.2 1.65  0.78 4.58  0.36 19.38  0.41* 67.97  13.02
MRI-2 0.5% w/w 0.5e1.2 1.65  0.78 5.58  0.37 20.24  0.39* 65.44  7.02*
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obvious region of newly formed bone could be localized inside, as
well as outside the site of CPC injection (Fig. 4).3.6. Histology and micro CT for bone volume quantification
In none of the histological sections an adverse tissue reaction or
signs of severe inflammation were found. Micro CT observation as
well as HE and EVG staining showed a uniform bone reaction in all
groups, and combined information from histological slides and
micro CT (Fig. 5a) allowed the location of the original defect site
within the condyle. Upon light microscopical inspection, all defect
areas appeared to be filled by newly formed trabecular bone. Bone
marrow-like tissue was observed in between the bone voids and
fibrotic tissue was absent. Despite the decalcification procedure,
still traces of the implanted CPC were present in both CPC and MRI
groups, whereas they could not be found in samples from the MRI/
BMP2 group.
The original 3  3 mm defect area was selected to quantify the
bone volume percentage. Eight weeks after implantation, the re-
sults showed significantly enhanced bone formation only in the
presence of BMP-2, whereas no differences were detected between
the other three groups (Fig. 5b).Fig. 3. In vitro BMP-2 release measured by a. ELISA and b. BRE-Luc assay. Both graphs
compare the release from HA-coated beads against not coated beads. Results from both
assays showed enhanced BMP-2 release in the presence of the coating. The BRE-Luc
assay showed that, in the presence of the coating, the amount of bioactive released
BMP-2 was relatively higher compared to the release in absence of coating.4. Discussion
The present study aimed to test the feasibility of a theranostic
agent, i.e. an agent which simultaneously is capable to enhance the
MR bone contrast, as well as enhance the osteogenic properties of
CaP bone cement. Both in vitro and in vivo assays were performed.
The TA as used, was a nanocomposite of silica beads, in which an
iron oxide core and a silane linker-modified and calcium phosphate
coated surface for BMP-2 immobilization were structurally inte-
grated. The main in vivo implantation results showed a long-term
MR contrast enhancement, as well as improved osteogenic capac-
ity, by means of new bone formation.
Theranostic agents are a class of imaging probes explored for the
simultaneous visualization of drug delivery and therapeutic out-
comes [8]. Conveniently, many imaging agents can be easily
upgraded to theranostic agents. For example, iron particles,
currently the most popular MR contrast agents [9], have been often
selected for theranostic applications, as their surface coating allows
straightforward chemical linkage and bioactive molecules loading
[10]. In an initial study from our group, USPIOs were directly
incorporated into CaP-based scaffolds, as enhancers of the implant-
to-bone contrast. Despite providing sufficient imaging contrast, this
approach had many practical drawbacks. Mainly, the ultra small
iron oxide particles (USPIOs) negatively affected the setting and
mechanical properties of the injectablematerial [11]. Therefore, in a
follow-up study, USPIOs were encapsulated into inert silica, with
the purpose to reduce aspecific reactivity in the cement setting
reaction [12]. In the present study, the same approach was used to
synthesize two sets of silica particles, both encapsulating iron ox-
ide, but differing by core size and iron particles-to-silica ratio. Be-
sides the advantage of reducing unspecific reactivity, mesoporous
silica has been extensively studied with regard to its applications
for drug delivery and loading of bioactive molecules [13e15].
As first principal results of this study, the characterization of the
particles and ex vivoMRI data were used for the selection of one TA
composition for the final animal work. Although the MRI-2 showed
a significant increase in final cement setting time, we regarded this
effect of lesser importance, as the increase from 18 to 20minwould
be irrelevant for clinical handling. In stead, the MRI-2 by visual
inspection exhibited a region of hypointensity, which at the MRI
settings used more closely resembled the original area of the CPC-
filled defect. It is important though to realize that shape mea-
surements with any iron-containingMRI contrast agent will always
be irreliable, as such agents are always be susceptible to so-called
blooming effects. This type of artifact indeed was seen at both
MRI-1 and MRI-2. It would ideally be possible to perform quanti-
tative assessments on this effect with phantom studies, combined
with proper calibration of the image thresholding. Such quantifi-
cation however was not the aim for the current work, where image
settings were always kept constant.
After proper imaging contrast was achieved, we focused on the
osteogenic protein. A recent study from Elhert et al. [16] sought to
investigate the immobilization methods of BMP-2 on ceramic bone
replacement materials. Only in the presence of the aminosilane
Fig. 4. In vivo MRI. Representative 2D slides selected from 3D-acquired datasets of rat femoral condyle defects from the four experimental groups, acquired by Zero Echo Time MRI
sequence at 4 and 8 weeks post-implantation. Red arrows indicate the location of the defect. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
Fig. 5. Micro CT and histology for bone volume quantification. a. Qualitative mCT and
histological evaluation. Representative 2D-mCT and corresponding H&E stained sec-
tions from the CPC group 8 weeks post-implantation. The dashed circle indicated the
original defect area. b. Quantitative evaluation of bone formation. Bone formation was
measured within the original defect area, in the four experimental groups, 8 weeks
after implantation. Bone percentage in all groups was around 60e70%, while the MRI/
BMP2 group showed a significantly enhanced bone formation (P < 0.05).
M. Ventura et al. / Biomaterials 35 (2014) 2227e22332232linker notable amounts of BMP-2 could be immobilized. Consid-
ering these results, in the present study, the same approach was
used to immobilize BMP-2 on the surface of the MRI-2 silica par-
ticles. Of course, also the amount of BMP-2 provided at the implant
site is determining for its function [17e19], and furthermore
appropriate amounts can vary among different scaffold materials.
For CPCs ranges from 2 to 30 mg have been investigated [20,21],
while several studies report enhanced bone formation already at
the lowest doses [22e24]. In the present study therefore a final
concentration ofw5 mg per defect was adsorbed onto the beads and
incorporated into each CPC scaffold.
The possibilities to further modulate BMP-2 release in terms of
kinetics and concentration ranges, have been extensively explored.
One option to modulate release is to provide the carrier with a
coating. In the present study, the silica particles were coated by
precipitated hydroxyapatite, following BMP-2 adsorption. The
study of Boix et al. showed that BMP-2 has high affinity for hy-
droxyapatite, mainly influenced by the abundance of calcium or
phosphate ions, especially at low pHs [25]. These results support
the hypothesis that in our study, BMP-2 might have higher affinity
for the coating rather than the functionalized silica support. It is
therefore realistic to expect a fast release of the coating from the
silica surface, together with the attached BMP-2. Based on the BRE-
Luc assays results, upon release, the coating also contributed to
preserve higher concentrations of bioactive BMP-2.
Finally, we tested in vitro the setting time and compressive
strength of the CPC. Such handling properties are often overlooked
but of critical interest to surgeons. It was shown that handling was
not significantly affected by the incorporation of the TA, corrobo-
rating the data of our previous study [12]. The material handling
remained acceptable within a range which still meets the clinical
demands when repairing non-loading sites [24].
The TA-CPCwas thereafter also tested in vivo, upon injection in a
femoral condyle defect model in rats. The animal model is a well-
M. Ventura et al. / Biomaterials 35 (2014) 2227e2233 2233established defect model for testing injectable as well as pre-set
bone substitute materials [26,27]. The relatively easy surgical pro-
cedure, together with the easily accessible location for imaging
procedures, makes this model optimal for the purposes of our
study. Again corroborating our previous data [12], standard non-
modified CPC was not distinguishable from the surrounding bone
tissue. In contrast, the TA-CPC remained detectable by MRI up to
eight weeks post-implantation. However, in most samples from the
MRI/BMP2 group, contrast was seen at 4 weeks, but no longer
observable after 8 weeks. Such observation is not due to a decay of
the generated signal, but rather indicative that CPC remodeling and
degradation was accelerated by the activity of BMP-2. Moreover,
the results of this group evidenced that the TA was released from
the CPC upon its degradation, but not incorporated into the newly
formed bone, as the contrast enhancement would still be detect-
able otherwise. This property makes the TA particularly attractive
for longitudinal and material degradation studies. Furthermore, for
these type of beads is has been described that upon release from
the scaffold, they can be cleared through intestinal macrophages
and, due to their size, renal filtration [28,29], overcoming toxic
accumulation issues. Finally, also the histological evaluations
proved that no traces of the implanted CPC could be retrieved in the
MRI-BMP/2 group, supporting the notion that indeed the MR
contrast disappearance 8 weeks post-implantation was solely due
to the CPC scaffold degradation.
5. Conclusions
Multimodal and multifunctional theranostic probes are forming
a cutting-edge technology, in which the advantages of both
advanced imaging and therapeutic strategies can be combined. In
the present study, we have described a bead-based formulation
composed of an iron oxide core for MR contrast enhancement,
embedded in a mesoporous silica matrix on which BMP-2 was
immobilized. Our strategy allowed to overcome negative interfer-
ence of the addition of a contrast agent to the biomaterial proper-
ties. Furthermore, bioactive BMP-2 could be efficiently released
from the carrier-beads, leading to localized and effective bone
regeneration. The described TA was shown to be suitable for lon-
gitudinal material degradation and bone healing studies.
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